Open AccessControlled Trial of Nifedipine and Bendroflumethiazide in Hypertension
Author(s) -
Lena Hallin,
Lennart Andrén,
Lennart Hansson
Publication year - 1983
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-198311000-00025
Subject(s) - nifedipine , supine position , placebo , medicine , blood pressure , essential hypertension , anesthesia , calcium , alternative medicine , pathology
In a double-blind study 30 patients with mild or moderate (World Health Organization classification I or II) hypertension were treated with either nifedipine, 20 mg twice a day, or bendroflumethiazide, 2.5 mg (+0.57 g KCl) twice a day for 24 weeks. All patients were then given a combination of half the initial dosage of both drugs for an additional period of 6 weeks. Nifedipine caused a significant reduction of both supine and standing blood pressures (16/10 and 11/5 mm Hg, respectively). Bendroflumethiazide also reduced both recumbent and standing blood pressures significantly (15/10 and 11/10 mm Hg, respectively). Combined treatment with nifedipine and bendroflumethiazide caused a further reduction of both supine and standing blood pressures. The total reduction compared with placebo was 23/12 mm Hg (p less than 0.001) and 17/11 mm Hg (p less than 0.001), respectively. There was no significant correlation between antihypertensive effect and age of patient.